16. Supplemental Disclosure of Cash Flow Information (Tables)

12 Months Ended

Dec. 31, 2016

Year Ended December 31,
	2016		2015
Cash paid for interest	$	1,441,160	$	624,896
Cash paid for income taxes	$	157,346	$	1,386,955
Non-cash investing and financing activities:
Accrued liabilities settled through the issuance of common stock and warrants	$	2,231,829	$	–
Exercise of stock options as reduction of notes payable, related party	$	–	$	2,500,000
Adjustment of goodwill	$	–	$	131,270
Assets acquired through capital leases	$	–	$	1,638,884
Acquisition of noncontrolling interest in Biohealth Medical Laboratory, Inc.	$	259,875
Acquisition of CollabRx	$	–	$	13,510,777
Conversions of preferred stock into common stock	$	37,823,000	$	25